Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B4
Source: 0001062993-25-010548
Chunk: 74

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B4
Chunk 74
---
 | 1,360,680 |     |   438,302 |     |   922,378 |   |
| Consulting fees                                           |     |                              |   284,946 |     |   455,814 |     |  (170,868 | ) |
| Salaries, wages and benefits                              |     |                              |   357,517 |     |   201,016 |     |   156,501 |   |
| General office, insurance and administration expenditures |     |                              |   539,696 |     |   177,810 |     |   361,886 |   |
| Business development and investor relations               |     |                              |   464,944 |     |    77,086 |     |   387,858 |   |
| Stock-based compensation                                  |     |                              |   112,277 |     |    35,953 |     |    76,324 |   |
|                                                           |     |                              | 3,120,060 |     | 1,385,981 |     | 1,734,079 |   |

Professional fees increased by $922,378 for the three months ended March 31, 2025, compared to the equivalent period in the prior year. The increase was primarily due to increases in legal and accounting fees related to the Company's operations. Professional fees include fees incurred for legal and accounting services that fluctuate from period to period based on the nature of the transactions the Company undertakes. The primary reason for the increase is due to increased regulatory requirements following the Company’s initial public offering and transition to U.S. domestic issuer status.

Consulting fees decreased by $170,968 for the three months ended March 31, 2025, compared to the equivalent period in the prior year. Consulting fees include fees paid to individuals and professional firms who provide advisory services to the Company and fluctuate from period to period based on the nature of the transactions the Company undertakes. The primary reason for the increase is due to decreased business activity in the current year compared to the prior year when the Company was focused on completing the initial public offering.

Salaries, wages and benefits increased by $156,501 for the three months ended March 31, 2025, compared to the equivalent period in the prior year. The increase was primarily due to an increase in headcount from the previous year.

General office, insurance and administration expenditures increased by $361,886 for the